U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188012) titled 'Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patie... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07189195) titled 'TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresect... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07189351) titled 'Comparing Muscle Energy Technique and Bowen Therapy for Pain, Movement, and Disability in ... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188454) titled 'The Effects of a Meditation Intervention on the Psychological Burden of Long-Term Care Pro... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187934) titled 'EVALUATION OF A FULLY AUTOMATED AI TOOL FOR EMBRYO RANKING' on Sept. 04. Brief Summary: T... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188285) titled 'Mass Spectrometry-based Immune Profiling in Autoimmune Diseases' on April 14. Brief Summa... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187700) titled 'Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disea... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188441) titled 'Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Inje... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187674) titled 'The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positi... Read More
U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188896) titled 'A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus N... Read More